Sarcura
Financiado
Cell Factory on chips: make Cell Therapies affordable and accessible to all pati...
Sarcura GmbH, an Austrian deep-tech company founded in November 2019, will develop and market a machine platform for the industrial GMP manufacturing of personalised cell therapeutics, such as CAR-T therapies.
We will contribute...
Sarcura GmbH, an Austrian deep-tech company founded in November 2019, will develop and market a machine platform for the industrial GMP manufacturing of personalised cell therapeutics, such as CAR-T therapies.
We will contribute to scale the global cell therapy manufacturing capacity of these lifesaving treatments from currently thousands of doses per year to hundreds of thousands of doses, cost effective and safe for all patients. Sarcura envisions to transform existing manufacturing paradigms by using leading-edge semiconductor technologies (such as integrated photonics) embedded in microfluidic liquid processing systems to bring bioprocess control to cellular level.
We believe that only by bringing together automation, integration (of additional functionality), miniaturization, and modularity we can achieve the required 100-fold increase in manufacturing capacity the cell therapy industry requires
Our initial focus is the development of a GMP ready, fully automated, industrial cell isolation device for the manufacturing of cell therapies. The device will include all necessary processing steps to handle the typical starting material of clinical cell therapy as well as provide integrated process analytics and quality control such as cell count, viability, phenotype characterization and other analytics
After launching the first single unit operation device for the Cell Isolation, further devices performing the Formulation, Gene Transfer and Expansion followed by an integrated end-to-end device will be developed. Finally, we aim to market an autonomous, self-optimising manufacturing system based on real-time manufacturing optimisation via AI driven (artificial intelligence) predictive process control.
Our product offer will include (a) desktop instruments, (b) single-use microfluidic cartridges, and (c) software and algorithms.
ver más
Duración del proyecto: 12 meses
Fecha Inicio: 2023-05-26
Fecha Fin: 2024-05-31
Fecha Fin: 2024-05-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIE-2022-SCALEUP-02-02:
Women TechEU
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
75K€
Líder del proyecto
SARCURA GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
